
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a promising biotechnology company due to their innovative approach to treating mental health conditions and potential for significant market opportunity with their COMP360 drug. The company's strong financials and successful trials, along with the FDA's support for psychedelic therapies and their focus on mood disorders and psychiatric diseases, make them a promising contender in the market. While there are risks involved with navigating regulations and maintaining exclusivity, the company's potential for international partnerships and partnerships in the US market could solidify their position as a major player in the industry. Additionally, the increasing acceptance of psychedelic drugs in treatment-resistant depression and potential for use in PTSD patients shows the growing demand for alternative treatment options, making Compass Pathways an attractive investment for a financial analyst.
Bears say
Compass Pathways is taking a measured approach to commercialization and setting realistic expectations for initial sales in '27, with potential upside due to efficiencies in administration and room utilization, but concerns remain around potential challenges with REMS and infrastructure. The company's partnership with the VA for studies in PTSD indicate a potential $1.4B peak sales opportunity in this indication. However, concerns regarding ESG considerations and potential risks in clinical development, commercialization, and pricing pose potential downside risks. The current valuation may not fully account for these potential risks and investors should approach this stock with caution.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares